Published in Cell Death Dis on October 15, 2015
Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma. BMC Cancer (2017) 0.75
Specific autoantigens identified by sera obtained from mice that are immunized with testicular germ cells alone. Sci Rep (2016) 0.75
TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis. Oncotarget (2016) 0.75
The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. Cell Death Dis (2017) 0.75
ABC transporters: from microorganisms to man. Annu Rev Cell Biol (1992) 19.49
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
Nasopharyngeal carcinoma. Lancet (2005) 7.16
The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 6.61
The c-Myc target gene network. Semin Cancer Biol (2006) 5.98
Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res (1996) 4.48
The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res (2001) 3.95
The myc oncogene: MarvelouslY Complex. Adv Cancer Res (2002) 3.68
Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res (2006) 3.12
Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res (2007) 2.68
A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev (1994) 2.65
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest (2009) 2.52
c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol (1999) 2.50
Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature (2014) 2.38
World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J (2006) 2.26
Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol (2013) 2.08
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood (2001) 1.84
Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J (2000) 1.69
The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell (2000) 1.63
Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet (2003) 1.57
Effects of the endocrine disruptors atrazine and PCB 153 on the protein expression of MCF-7 human cells. J Proteome Res (2009) 1.49
A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem (1990) 1.43
MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Cancer Res (2012) 1.32
MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. Oncogene (2014) 1.27
Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res (2009) 1.23
An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res (2006) 1.23
How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Semin Cancer Biol (2009) 1.13
Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology (2009) 1.09
Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology (2009) 1.09
Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene (2012) 1.08
C-MYC: evidence for multiple regulatory functions. Semin Cancer Biol (1990) 1.06
c-myc amplification in ovarian cancer. Gynecol Oncol (1990) 1.05
The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Virol Sin (2015) 1.05
Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Mol Cancer (2013) 1.04
Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol (2010) 1.02
Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chin J Cancer (2014) 1.02
c-myc oncogene family expression in glioblastoma and survival. Surg Neurol (1999) 1.01
Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem (2010) 1.01
Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res (2011) 1.00
Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene (2009) 0.99
Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol (2006) 0.98
The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer (2008) 0.96
Nasopharyngeal carcinoma. Surg Oncol Clin N Am (2015) 0.96
FUSE binding protein 1 interacts with untranslated regions of Japanese encephalitis virus RNA and negatively regulates viral replication. J Virol (2011) 0.96
AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts. J Biol Chem (2003) 0.95
Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J Biol Chem (2004) 0.93
2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics (2008) 0.93
Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells. Chin J Cancer (2014) 0.92
Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol (2000) 0.90
ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Front Oncol (2012) 0.90
Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood (2013) 0.90
c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Biosci (Landmark Ed) (2009) 0.90
c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling. J Cell Biochem (2006) 0.89
Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc Natl Acad Sci U S A (2009) 0.88
Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. Oncol Rep (2012) 0.88
Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma. J Transl Med (2014) 0.88
Far upstream element binding protein 1 activates translation of p27Kip1 mRNA through its internal ribosomal entry site. Int J Biochem Cell Biol (2011) 0.88
The c-myc activation in cervical carcinomas and HPV 16 infections. Mutat Res (2004) 0.87
Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. J Exp Clin Cancer Res (2004) 0.86
Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma. BMC Cancer (2011) 0.85
Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma. FEBS J (2013) 0.84
Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Int J Mol Sci (2015) 0.82
Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Mod Pathol (2013) 0.81
LMP1 stimulates the transcription of eIF4E to promote the proliferation, migration and invasion of human nasopharyngeal carcinoma. FEBS J (2014) 0.81
Evaluation of stem-like side population cells in a recurrent nasopharyngeal carcinoma cell line. Cancer Cell Int (2014) 0.81
Inhibition of autophagy protects against PAMAM dendrimers-induced hepatotoxicity. Nanotoxicology (2014) 0.81
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. J Cancer Res Clin Oncol (2015) 0.80
Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma. BMC Cancer (2008) 0.80
Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation. Cytometry B Clin Cytom (2004) 0.79
TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Lett (2014) 0.78
[Establishment of three-dimensional culture models related to different stages of nasopharyngeal carcinogenesis]. Ai Zheng (2005) 0.78
Suppression of c-Myc is involved in multi-walled carbon nanotubes' down-regulation of ATP-binding cassette transporters in human colon adenocarcinoma cells. Toxicol Appl Pharmacol (2014) 0.78
Detection of c-myc gene expression in nasopharyngeal carcinoma by nonradioactive in situ hybridization and immunohistochemistry. Chin Med J (Engl) (1997) 0.78
Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis. Int J Cancer (2015) 0.78
A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA. J Immunol (2015) 0.77
[MYC protein and proteins antigenically related with MYC in acute lymphoblastic leukemia]. Rev Invest Clin (1991) 0.76
Carcinoid syndrome and intravenous cyproheptadine. Anaesthesia (1987) 0.76
Nonkeratinizing undifferentiated nasopharyngeal carcinoma. Head Neck Pathol (2012) 0.76
Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent. Cell Mol Immunol (2015) 0.76